Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.42 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15405716 | 1.00 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL31681344 | 1.00 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL31758244 | 1.00 | MDM2 (0.42) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29430340 | 0.98 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL3431396 | 0.98 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29358841 | 0.98 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL15521023 | 0.98 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL3725103 | 0.98 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL29384293 | 0.98 | MDM2 (0.43) | MDM2TLR2HDAC3HDAC6MDM4 | |
| SCHEMBL30532186 | 0.95 | MDM2 (0.41) | MDM2TLR2HDAC3HDAC6MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026086847-A1 | CYCLOPEPTIDE DRUG CONJUGATE AND USE THEREOF | 中山医诺维申新药研发有限公司 | 2026-04-30 | — | — | WO | disclosed |
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-12539335-B2 | Tricyclic polypeptide conjugated drug and use thereof | CONJUSTAR (ZHUHAI) BIOLOGICS CO., LTD. (CN) | 2026-02-03 | — | — | US | disclosed |
| EP-4650362-A1 | NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| EP-3746467-B1 | MODIFIED LIPIDATED RELAXIN B CHAIN PEPTIDES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2025-10-08 | — | — | EP | disclosed |
| US-20250277001-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-04 | — | — | US | disclosed |
| US-20250263440-A1 | CD38-BINDING AGENTS AND USES THEREOF | PEPTIDREAM INC. (JP) | 2025-08-21 | — | — | US | disclosed |
| EP-3727461-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2025-07-09 | — | — | EP | disclosed |
| WO-2023066314-A1 | BICYCLIC PEPTIDE LIGAND FOR NECTIN-4 AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023061482-A1 | EPHA2 BICYCLIC PEPTIDE LIGAND AND CONJUGATE THEREOF | 海思科医药集团股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| WO-2023051396-A1 | TRICYCLIC POLYPEPTIDE CONJUGATED DRUG AND USE THEREOF | 南京明德新药研发有限公司 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023028008-A2 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | RIVER 2 RENAL CORP. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4139326-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2023020485-A1 | POLYPEPTIDE DRUG CONJUGATE HAVING NOVEL STRUCTURE AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-02-23 | — | — | WO | disclosed |
| EP-4053145-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BicycleTx Limited (GB) | 2022-09-07 | — | — | EP | disclosed |
| US-20220169677-A1 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2022-06-02 | — | — | US | disclosed |
| EP-3993874-A1 | CD38-BINDING AGENTS AND USES THEREOF | PeptiDream Inc. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3727460-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263440-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, IGSF11, MCL1 | MDM2 3159/4885TLR2 3833/4885HDAC3 1745/4885 |
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | NRP1, FLT1, KDR | MDM2 968/4885TLR2 2224/4885HDAC3 1571/4885 |
| US-20250277001-A1 | PEPTIDE DERIVATIVES AND RELATED USES AS OREXIN AGONISTS | HCRTR2, HCRTR1, CRH | MDM2 4498/4885TLR2 4407/4885HDAC3 969/4885 |
| US-20220169677-A1 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | NRP1, KDR, FLT1 | MDM2 835/4885TLR2 1884/4885HDAC3 2100/4885 |
| US-12539335-B2 | Tricyclic polypeptide conjugated drug and use thereof | NECTIN4, SELPLG, ITGB4 | MDM2 3252/4885TLR2 108/4885HDAC3 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.